MTNB (Matinas BioPharma Holdings) Short-Term Debt to Capital

Matinas BioPharma (MTNB) is developing advanced drug delivery methods in New Jersey laboratories, utilizing external plants for stable production. The company's price chart demonstrates asset dynamics that depend on test results rather than market cycles; meanwhile, the metric stands at 0.00. The high commitment of research scientists and the hiring of specialized lawyers for clinical trial regulations ensure sustainable business growth.

This ratio measures the proportion of liabilities maturing within one year relative to equity, allowing for an assessment of the company's reliance on short-term financing for current operations. By analyzing the short-term debt-to-equity ratio, an investor can determine how effectively Matinas BioPharma (MTNB) balances R&D costs in New Jersey and contract manufacturing payments, which determines the overall financial stability of the business.